Continuous Renal Replacement Therapy (CRRT) Market Forecasts to 2028 – Global Analysis By Product (Compliant Dialysates and Replacement Fluids, Disposables, Hemofilters and Other Products), Modality (Slow Continuous Ultra-Filtration (SCUF), Continuous Ven

Continuous Renal Replacement Therapy (CRRT) Market Forecasts to 2028 – Global Analysis By Product (Compliant Dialysates and Replacement Fluids, Disposables, Hemofilters and Other Products), Modality (Slow Continuous Ultra-Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD) and Continuous Venovenous Hemodiafiltration (CVVHDF)), Age Group (Adults and Pediatrics /Neonates), End User (Hospitals, Ambulatory Centers, Specially Clinics and Other End Users) and Geography

According to Stratistics MRC, the Global Continuous Renal Replacement Therapy (CRRT) Market is accounted for $1.31 billion in 2022 and is expected to reach $2.23 billion by 2028 growing at a CAGR of 9.3% during the forecast period. A common form of treatment for critically ill patients with acute kidney injury (AKI), particularly those with unstable hemodynamics, is continuous renal replacement therapy (CRRT). It includes the process of removing solutes from blood via hemofiltration, hemodialysis, or a combination of the two.

According to the American Hospital Association, there were 208 federal government hospitals, 625 nonfederal psychiatric hospitals, and 5,141 community hospitals in the country in 2021. The demand for CRRT systems is also rising due to the significant rise in AKI hospital admissions and the growing geriatric population, which is fueling market expansion.

Market Dynamics:

Driver:

Increase in acute kidney injury and chronic kidney diseases

The main risk factors for acute kidney injury are diabetes, hypertension, and an ageing population. Diabetes prevalence is rising quickly across the globe. As a result, the number of patients with acute kidney injury is growing along with the prevalence of diabetes. Growing awareness among medical professionals could lessen its occurrence and enhance the management of underlying diseases in the elderly population.

Restraint:

High procedural cost

People in emerging economies value affordability, so they favour lower-cost goods. Despite the high cost in developing nations, a large portion of the population cannot afford these measures because of their low purchasing power. This restricts both the developed and developing world's demand for and adoption of this therapy.

Opportunity:

Implementation of new technologies

Technology advancements in equipment design have greatly benefited the use of therapy in critically ill patients. These innovations have significantly broadened the scope of extracorporeal therapies in the ICU. Additionally, software integration is likely to emerge as a brand-new tool for cutting-edge machinery.

Threat:

Stringent healthcare regulations

Companies are vulnerable to a changing regulatory environment because they are subject to a number of existing laws and regulations, and non-compliance will likely have a negative impact on their operations, financial condition, and business. The fact that businesses' operations and goods are subject to a variety of government regulations as healthcare industry participants is a hindrance to the market's expansion.

Covid-19 Impact:

The overall impact of COVID-19 remains positive on the market. The pandemic has significantly increased the demand for renal replacement fluids on a global scale. When compared to historical US populations, the demand for RRT among COVID-19 patients has increased five times. China and Italy, for example, reported AKI rates as high as 29%, according to a study by the International Society of Nephrology 2020. Early implementation of continuous renal replacement therapy (CRRT) is crucial for reducing the incidence of AKI, which is on the rise as a result of COVID-19 infection.

The Continuous Venovenous Hemodiafiltration (CVVHDF) segment is expected to be the largest during the forecast period

The continuous venovenous hemodiafiltration (CVVHDF) segment is estimated to have a lucrative growth, due to the increase in dialysis procedures. This treatment modality results in comprehensive removal and replacement of solutes and fluids within the blood. It also includes principles of diffusion and convection, hence propelling the growth of the market.

The Adults segment is expected to have the highest CAGR during the forecast period

The adults segment is anticipated to witness the fastest CAGR growth during the forecast period, due to various regulatory approvals for adult and rise in development of novel products. Additionally, adoption of various growth strategies by various market players are creating lucrative opportunities in the segment.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to rising technological advancement, surging healthcare expenditure. This is primarily attributed to increase in number of initiatives along with enhanced investments for the overall R&D of products. Additionally, surge in focus of leading manufacturers on expanding their geographical presence is the factor driving the region growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to rise in geriatric population and increasing incidences of acute kidney injury. High adoption rates of new technologies in continuous renal replacement therapy and the presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.

Key players in the market

Some of the key players in Continuous Renal Replacement Therapy (CRRT) market include Asahi Kasei Corporation, B. Braun Medical Inc., Baxter International Inc., Chongqing Shanwaishan Science and Technology Co., Ltd., Fresenius Medical Care AG & Co. KGaA, Infomed SA, Medica SpA, Medical Components, Inc., Medites Pharma Spol. S.R.O., Medtronic Plc, Nikkiso Co., Ltd., Ningbo Tianyi Medical Appliance Co., Ltd, NIPRO Corporation, NxStage Medical, Inc. and Toray Medical Co., Ltd.

Key Developments:

In February 2021, DaVita accomplished its first position by including a secure telehealth platform, DaVita Care Connect, into its home dialysis program. It is one of the various connective technologies in its suite of services designed to improve outcomes and the care experience for patients deciding to treat at home.

In December 2020, Medtronic plc announced the launch of the Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine. This technique is indicated to be used in acute kidney injury or fluid overloaded patients that need hemodialysis. It is planned to supply continuous renal replacement therapy (CRRT) to patients weighing between 2.5 & 10 kg.

In April 2020, Fresenius Medical Care, a worldwide provider of dialysis products and services, has announced the release of an advisory that calls for clinical care principles for patients with advanced chronic kidney during the pandemic crisis. The advisory states that patients who need renal replacement therapy during the COVID-19 crisis should still be offered the treatment decided in consultation with their physicians.

Products Covered:
• Dialysates and Replacement Fluids
• Disposables
• Hemofilters
• Bloodline Sets & Tubes
• CRRT Systems
• Other Products

Modalities Covered:
• Slow Continuous Ultra-Filtration (SCUF)
• Continuous Venovenous Hemofiltration (CVVH)
• Continuous Venovenous Hemodialysis (CVVHD)
• Continuous Venovenous Hemodiafiltration (CVVHDF)

Age Groups Covered:
• Adults
• Pediatrics /Neonates

End Users Covered:
• Hospitals
• Ambulatory Centers
• Specially Clinics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements